Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2014 2
2016 4
2017 2
2018 2
2020 3
2021 2
2022 5
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study.
Miyake M, Shimizu T, Oda Y, Tachibana A, Ohmori C, Itami Y, Kiba K, Tomioka A, Yamamoto H, Ohnishi K, Nishimura N, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Fujii T, Tanaka N, Fujimoto K. Miyake M, et al. Among authors: kiba k. Jpn J Clin Oncol. 2023 Mar 7;53(3):253-262. doi: 10.1093/jjco/hyac186. Jpn J Clin Oncol. 2023. PMID: 36484294
Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort.
Miyake M, Nishimura N, Oda Y, Miyamoto T, Ohmori C, Takamatsu N, Itami Y, Tachibana A, Matsumoto Y, Kiba K, Tomioka A, Yamamoto H, Okajima E, Masaomi K, Sakamoto K, Tomizawa M, Shimizu T, Ohnishi K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K; Nara Urological Research and Treatment Group. Miyake M, et al. Among authors: kiba k. Jpn J Clin Oncol. 2024 Mar 9;54(3):329-338. doi: 10.1093/jjco/hyad170. Jpn J Clin Oncol. 2024. PMID: 38061911
Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study.
Shimizu T, Miyake M, Nishimura N, Inoue K, Fujii K, Iemura Y, Ichikawa K, Omori C, Tomizawa M, Maesaka F, Oda Y, Miyamoto T, Sakamoto K, Kiba K, Tanaka M, Oyama N, Okajima E, Fujimoto K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K. Shimizu T, et al. Among authors: kiba k. Cancers (Basel). 2022 Mar 29;14(7):1735. doi: 10.3390/cancers14071735. Cancers (Basel). 2022. PMID: 35406508 Free PMC article.
Rapid multiplex PCR assay for simultaneous detection of Neisseria gonorrhoeae and Chlamydia trachomatis in genitourinary samples: A 30-minute assay.
Inoue T, Chihara Y, Kiba K, Hirao S, Tanaka M, Yoneda T, Saka T, Beppu KI, Furubayashi K, Takashima M, Nagai H, Kobayashi H, Fujimoto K. Inoue T, et al. Among authors: kiba k. J Microbiol Methods. 2021 Jan;180:106103. doi: 10.1016/j.mimet.2020.106103. Epub 2020 Nov 12. J Microbiol Methods. 2021. PMID: 33188803 Free article.
First-line pembrolizumab for patients with early relapsing urothelial carcinoma after perioperative chemotherapy: a retrospective analysis of bladder cancer and upper urinary tract cancer.
Nishimura N, Miyake M, Shimizu T, Matsubara T, Miyamoto T, Sakamoto K, Yamada A, Matsumoto Y, Yoshikawa M, Ichikawa K, Omori C, Maesaka F, Oda Y, Kiba K, Tomioka A, Hosokawa Y, Tanaka M, Otani T, Fujimoto K. Nishimura N, et al. Among authors: kiba k. Int J Clin Oncol. 2022 Nov;27(11):1733-1741. doi: 10.1007/s10147-022-02230-9. Epub 2022 Aug 27. Int J Clin Oncol. 2022. PMID: 36029377
21 results